Combined PARP and PD-L1 inhibition: a promising treatment option for relapsed small-cell lung cancer

J Thorac Dis. 2024 Jun 30;16(6):4075-4078. doi: 10.21037/jtd-24-269. Epub 2024 Jun 25.

Authors

Naohiro Yanagimura¹, Satoshi Watanabe¹, Toshiaki Kikuchi¹

Affiliation

¹ Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

No abstract available

Keywords: Small-cell lung cancer (SCLC); durvalumab; olaparib.

Publication types

Editorial
Comment